Profil:
Selvita SASelvita pharma posts PLN 1.0 mln attributable net loss in Q1 '25, below expectations
Pharma firm Selvita posted PLN 1.0 million (EUR 235,800) of attributable net loss in the first quarter of 2025, the company said in a report.
PLN mln
The results reported are presented, with the exception of EBITDA (excluding the incentive programme). EBITDA reported in the first quarter of 2025 was PLN 14.1 million (EUR 3.3 mln).
1Q2025 | results | consensus | difference | y/y | q/q |
Revenues | 91.3 | 91.9 | -0.6% | 18.0% | -7.0% |
EBITDA adj. | 14.9 | 15.6 | -4.4% | 27.4% | -28.4% |
EBIT | 0.3 | 2.7 | -89.0% | - | -95.4% |
Atrib. net profit | -1.0 | 1.3 | - | - | - |
EBITDA margin | 16.3% | 17.4% | -1.05 | 1.20 | -4.86 |
EBIT margin | 0.3% | 2.3% | -1.98 | 3.04 | -6.29 |
net margin | -1.1% | 1.3% | -2.42 | 1.62 | -4.76 |
doa/ nl/